Parkinson Platform Noord Nederland

Fritz Jakob Heinrich Lewy (1885–1950) described the eosinophilic intraneuronal inclusion bodies, later named after him, while studying the neuropathology of Parkinson's disease at Alois Alzheimer's laboratory (Munich, Germany) in 1912.1 In 1962, neuropathologist John Woodard (Camarillo State Hospital, CA, USA) reported neuropsychiatric symptoms and cognitive decline in 27 patients with autopsy-proven Lewy body disease, of whom only about a quarter had parkinsonian symptoms.2 Over the following decades, Kenji Kosaka (Yokohama City University, Yokohama, Japan) and others from Japan reported detailed autopsies of more than 20 patients with a variable distribution of Lewy bodies in their brain stem and cerebral cortex, who clinically presented with varying amounts of cognitive impairment, and neuropsychiatric and motor symptoms.